City of Hope Expert Highlights Critical Gaps in Precision Medicine Implementation for Cancer Care
核心洞察
Patient disengagement from precision medicine services often stems from fear of cancer (搜索) diagnosis, language barriers, and poor care coordination, requiring improved trust-building and communication strategies.
Only 25-30% of eligible patients receive lung cancer (搜索) screening tests, highlighting a significant gap in early detection efforts compared to other cancer (搜索) screening programs like mammography.
Despite transformative advances in genomic testing for lung cancer (搜索) treatment, only 60-70% of practices effectively utilize molecular markers (搜索), with some physicians uncertain about interpreting results.
Dr. Edward Kim, physician-in-chief at City of Hope (搜索) Orange County, has identified several critical challenges hindering the effective implementation of precision medicine in cancer (搜索) care, particularly emphasizing the issue of patient leakage and gaps in genomic testing utilization.
Patient leakage - where individuals disengage from their care pathway - represents a significant obstacle in delivering precision medicine services. "Every patient I've met and their family members, they still remember the day when they heard that word cancer (搜索)," says Kim, highlighting how the emotional impact of diagnosis can trigger discontinuation of care.
Multiple factors contribute to patient disengagement, including:
- Language and cultural barriers
- Logistical challenges in care coordination
- Complex healthcare system navigation
- Trust issues between patients and healthcare teams
Screening and Early Detection Challenges
The implementation of precision medicine faces particular challenges in early detection and screening programs. For lung cancer (搜索), despite established screening protocols using low-dose CT scans for high-risk individuals, only 25-30% of eligible patients receive recommended screening tests. This falls significantly short of screening rates for other cancers, such as breast cancer (搜索), where mammography participation exceeds 90%.
Genomic Testing Implementation Gaps
In advanced lung cancer (搜索) treatment, where genomic testing has revolutionized care approaches, significant practice gaps persist. While molecular testing can identify 9-10 different markers with targeted treatments - many available as oral medications rather than traditional chemotherapy - adoption remains inconsistent.
"Not everyone is using these markers," Kim explains, noting that only 60-70% of practices effectively utilize genomic testing. This gap is particularly concerning given that targeted therapies have dramatically improved survival rates, with some patients now living years rather than the previous 6-9 month median survival with traditional chemotherapy.
Healthcare System Barriers
Several systematic challenges impede optimal implementation:
- Fragmented electronic health records
- Limited interoperability between systems
- Delays in tissue sampling and genomic testing (10-14 days)
- Varying levels of physician expertise in interpreting molecular data
Kim emphasizes that approximately 20% of physicians report uncertainty about interpreting genomic markers (搜索) and determining appropriate treatment courses. This challenge is particularly acute for community-based oncologists who treat multiple cancer (搜索) types.
Future Directions
Looking ahead, Kim envisions leveraging advanced technologies, including AI, to better identify high-risk patients and streamline care coordination. However, he acknowledges that significant work remains to overcome current data infrastructure limitations and improve system integration.
"It is vitally important that we continue this precision medicine course, treating each person as an individual," Kim concludes, emphasizing that personalized approaches based on unique genomic characteristics represent the future of cancer (搜索) care.